Company intelligence / Profile preview

CohBar, Inc.

Menlo Park, California, United Statescohbar.com ↗

Ownership: Public · CWBR
Employees: ~10
Development stage: Other

Overview

CohBar was a clinical-stage biotechnology company that developed mitochondria-derived therapeutic peptides. The company had advanced CB4211 to Phase 1/2 clinical trials for NASH and was working on CB5138-3 for IPF. As of May 2025, the company is no longer operating.

Therapeutic areas: GastroenterologyPulmonologyCardiovascularMetabolic DisordersEndocrinologyRare Diseases
Modalities: Mitochondrial-derived peptide therapeuticsPeptide therapeutics
Industry: Biotech

Drug pipeline

5 assets

MOTS-c

4 more assets in the full pipeline.

Request access →

Partnerships

Academic institutionsPharmaceutical research centersProposed merger with Morphogenesis (announced in 2023)

Financials

Market cap: $1.2M
Total revenue: $0
Enterprise value: $-11.1M

Beyond the preview

Go deeper on CohBar, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CohBar, Inc..

Explore the full profile